UP!

TMO $524.05

TMO target price
524.05
0
715
Type
Public
Traded as NYSE: TMO
S&P 500 Component
Industry Laboratory equipment
Founded 2006 by merger of Thermo Electron and Fisher Scientific
Headquarters Waltham, Massachusetts, USA
Key people
Marc N. Casper (President & CEO)
Joe Beery (CIO)
Products Analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics
Revenue Increase$18.27 billion (2016)
Net income
Increase$2.45 billion (2016)
Number of employees
65,000 (2017)
Website www.thermofisher.com

Thermo Fisher Scientific is an American multinational biotechnology product development company, created in 2006 by the merger of Thermo Electron and Fisher Scientific. In April 2013, after a competitive bidding with Hoffmann-La Roche, Thermo Fisher acquired Life Technologies Corp for $13.6 billion in a deal that would rank the firm as one of the leading companies in the genetic testing and precision laboratory equipment markets.

Thermo Electron was co-founded in 1956 by George N. Hatsopoulos and Peter M Nomikos. Hatsopoulos is a MIT PhD in mechanical engineering and Nomikos a Harvard Business School graduate. It focused on providing analytical and laboratory products and services, and had revenues of over $2 billion in 2004.

Fisher Scientific was founded in 1902 by Chester G. Fisher from Pittsburgh. It focused on providing laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety, and education.

On May 14, 2006, Thermo Electron and Fisher Scientific announced that they would merge in a tax-free, stock-for-stock exchange; the merged company was named Thermo Fisher Scientific. On November 9, 2006, the companies announced that the merger had been completed. However, the Federal Trade Commission ruled that this acquisition was anticompetitive with regard to centrifugal evaporators, requiring Fisher to divest Genevac. In April 2007, Genevac was sold to Riverlake Partners LLC and the merger closed with FTC approval.

Currently, the company's products are sold under the brand names of Thermo Scientific, Fisher Scientific, and several other recognized brand names (e.g. Chromacol, Nalgene, Cellomics, Pierce Protein Research and Fermentas). According to company figures, 46% of its sales are in life sciences, 20% in healthcare, and 34% in industrial/environmental and safety.

Thermo Fisher has offices and operations in many countries, notably the U.S. and in Europe.

In May 2011, Thermo Fisher Scientific Inc. bought Phadia to expand in testing for allergies and autoimmune diseases for €2.47 billion ($3.5 billion) in cash purchase.

In 2013 Thermo Fisher agreed to buy Life Technologies for $13.6 billion. The sale was completed on 4 February 2014, and the Life Technologies brand became part of the Life Sciences Solutions Group of Thermo Fisher Scientific.

In February 2015, the company announced it would acquire Advanced Scientifics for $300 million in a cash-deal. ASI designs, manufactures and delivers technologies used in bioprocessing solutions. In June 2015, the company announced its intention to acquire Alfa Aesar, a global manufacturer of research chemicals for $405 million from Johnson Matthey, and the acquisition was completed at the end of September

In January 2016, the company announced it would acquire Affymetrix for $1.3 billion. On May 27, 2016, the company announced it would acquire FEI Company for $4.2 billion, a manufacturer of electron microscopes. This acquisition is anticipated to close in early 2017 and will contribute to the growth of Thermo's Analytical Instruments business group. In November the company announced it would acquire MTI-GlobalStem, a previously privately held company that develops reagents for cell transfection, neurobiology and stem cell research.

In February 2017, the company acquired Finesse Solutions, Inc., developer of scalable control automation systems and software for bioproduction after receiving early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The transaction was completed a day later. In March, the company announced it would acquire Core Informatics, provider of cloud-based platforms supporting scientific data management. In May, the company announced it would acquire CDMO, Patheon, for $7.2 billion.

The following is an illustration of the company's major mergers and acquisitions and historical predecessors (this is not a comprehensive list):

Scientific Materials Co.
(Est 1902)

Scientific Supplies, Ltd
(Acq 1925)

Eimer & Amend
(Acq 1940)

E. Machlett & Sons
(Acq 1957)

Janssen Chimica

Eastman Kodak Company
(Organic Chemicals div)

Apogent Technologies Inc.
(Acq 2004)

Acquire Athena Diagnostics
(Acq 2006)

Kendro Laboratory Products
(Acq 2005)

Rupprecht and Patashnick Co., Inc.
(Acq 2005)

NITON LLC
(Acq 2005)

InnaPhase Corporation
(Acq 2004)

US Counseling Services, Inc.
(Acq 2004)

Jouan SA
(Acq 2004)

Laboratory Management Systems, Inc.
(Acq 2003)

Phadia
(Acq 2011)

Caltag Laboratories

Zymed

CellzDirect

BioSource

InforMax

Panvera

Dynal

Molecular Probes

Ethrog Biotechnology

Research Genetics, Inc
(Acq 1999)

NOVEX

Applied Biosystems
(Merged 2008)

Advanced Scientifics
(Acq 2015)

Alfa Aesar
(Acq 2015)

Genetic MicroSystems
(Acq 1999)

Neomorphic
(Acq 2000)

ParAllele Bioscience

USB Corporation
(Acq 2008)

Panomics
(Acq 2008)

True Materials
(Acq 2000)

eBioscience
(Acq 2012)

FEI Company
(Est 1971 as Field Electron and Ion Co. Merged 1997)

Philips Electron Optics
(Merged 1997)

Micrion
(Acq 1999)

MTI-GlobalStem
(Acq 2016)

Finesse Solutions, Inc.
(Acq 2017)

Core Informatics
(Acq 2017)

MOVA
(Acq 2004)

Banner Pharmacaps
(Acq 2013)

Royal DSM NV
(Pharmaceutical div, merged 2014)

Gallus Pharmaceuticals
(Acq 2014)

Agere Pharmaceuticals
(Acq 2015)

Source:

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q3 2022 2022-10-25 Future report Set alerts
Q2 2022 2022-07-28 5.51 5.51
Q1 2022 2022-04-28 7.25 7.25
Q4 2021 2022-02-02 6.54 6.54
Q3 2021 2021-10-27 5.76 5.76
Q2 2021 2021-07-28 5.60 5.60
Q1 2021 2021-04-29 7.21 7.21
Q4 2020 2021-02-01 7.09 7.09
Q3 2020 2020-10-21 5.63 5.63
Q2 2020 2020-07-22 3.89 3.89

Ratings

2016-07-06 Reiterated Rating Goldman Sachs Group Inc. Buy
2016-05-29 Reiterated Rating Leerink Swann Buy
2016-05-27 Boost Price Target Mizuho Buy $166.00 to $170.00
2016-05-27 Reiterated Rating BTIG Research Neutral
2016-05-19 Reiterated Rating Morgan Stanley Buy
2016-05-19 Reiterated Rating Mizuho Buy $163.00 to $166.00
2016-05-11 Reiterated Rating Bank of America Buy $163.00
2016-05-11 Reiterated Rating Bank of America Corp. Buy $163.00
2016-05-03 Reiterated Rating Mizuho Buy $160.00 to $163.00
2016-04-30 Reiterated Rating Morgan Stanley Buy
2016-04-30 Reiterated Rating Leerink Swann Buy
2016-04-29 Downgrade Jefferies Group Buy to Hold
2016-04-04 Boost Price Target Mizuho Buy $150.00 to $160.00
2016-03-23 Boost Price Target Goldman Sachs $156.00
2016-03-23 Boost Price Target Goldman Sachs Group Inc. $156.00
2016-03-21 Reiterated Rating Leerink Swann Outperform
2016-03-21 Reiterated Rating Evercore ISI Buy $145.00
2016-03-02 Boost Price Target Topeka Capital Markets Buy $145.00 to $155.00
2016-01-31 Reiterated Rating Deutsche Bank Buy
2016-01-31 Reiterated Rating BTIG Research Neutral
2016-01-31 Reiterated Rating Deutsche Bank AG Buy
2016-01-29 Lower Price Target Stifel Nicolaus $158.00 to $150.00
2016-01-29 Lower Price Target Mizuho Buy $150.00
2016-01-29 Lower Price Target Leerink Swann Outperform $149.00 to $141.00
2016-01-29 Lower Price Target KeyBanc Overweight $152.00 to $150.00
2016-01-29 Lower Price Target Deutsche Bank $160.00 to $152.00
2016-01-29 Lower Price Target Barclays Overweight $165.00 to $160.00
2016-01-29 Lower Price Target KeyCorp Overweight $152.00 to $150.00
2016-01-29 Lower Price Target Barclays PLC Overweight $165.00 to $160.00
2016-01-13 Reiterated Rating BTIG Research Neutral
2016-01-11 Boost Price Target Stifel Nicolaus Buy $150.00 to $158.00
2016-01-07 Boost Price Target Cowen and Company $160.00
2016-01-06 Initiated Coverage Deutsche Bank Buy $160.00
2016-01-06 Initiated Coverage Avondale Partners Outperform $168.00
2015-12-08 Upgrade Goldman Sachs Buy to Conviction-Buy $146.00 to $158.00
2015-11-24 Lower Price Target Goldman Sachs Buy $148.00 to $146.00
2015-10-22 Reiterated Rating BTIG Research Neutral
2015-10-15 Lower Price Target Citigroup Inc. Buy $152.00 to $149.00
2015-10-06 Initiated Coverage Argus Buy $145.00
2015-10-02 Lower Price Target Cowen and Company $150.00 to $140.00
2015-07-23 Boost Price Target Leerink Swann Outperform $141.00 to $149.00
2015-07-23 Boost Price Target Robert W. Baird Outperform $148.00 to $160.00
2015-07-23 Boost Price Target Mizuho Buy $150.00 to $160.00
2015-07-02 Reiterated Rating Barclays Overweight $165.00
2015-05-21 Reiterated Rating Jefferies Group Buy $150.00 to $155.00
2015-05-21 Boost Price Target JPMorgan Chase & Co. Overweight $145.00 to $150.00
2015-05-21 Boost Price Target Barclays Overweight $160.00 to $165.00
2015-04-23 Set Price Target Cantor Fitzgerald Buy $148.00
2015-04-23 Reiterated Rating BTIG Research Neutral
2015-01-30 Reiterated Rating Cantor Fitzgerald Buy $148.00
2015-01-30 Reiterated Rating BTIG Research Neutral
2015-01-21 Boost Price Target Robert W. Baird Outperform $142.00 to $144.00
2015-01-07 Initiated Coverage Barclays Overweight
2014-12-16 Initiated Coverage KeyBanc Buy $144.00
2014-10-23 Reiterated Rating Stifel Nicolaus Buy $150.00 to $140.00
2014-10-03 Initiated Coverage ING Group Neutral $110.00 to $130.00
2014-10-02 Initiated Coverage BTIG Research Neutral
2014-09-08 Initiated Coverage Morgan Stanley Overweight $146.00
2014-08-11 Initiated Coverage Stifel Nicolaus Buy $150.00
2014-07-24 Reiterated Rating Macquarie Outperform $130.00 to $135.00
2014-07-17 Initiated Coverage Citigroup Inc. Buy
2014-05-22 Lower Price Target Leerink Swann $139.00 to $133.00
2014-05-22 Boost Price Target Cowen and Company $125.00 to $135.00
2014-04-28 Upgrade Ned Davis Research Sell to Neutral
2014-04-11 Reiterated Rating Goldman Sachs Buy $153.00 to $151.00
2014-03-21 Boost Price Target Bank of America Buy $142.00
2014-03-21 Upgrade Goldman Sachs Buy $128.00 to $142.00
2014-02-20 Upgrade Goldman Sachs Neutral to Buy $114.00 to $153.00
2014-02-11 Initiated Coverage JPMorgan Chase & Co. Overweight $135.00
2014-01-31 Boost Price Target Leerink Swann Outperform $107.00 to $130.00
2014-01-31 Boost Price Target Cantor Fitzgerald $128.00 to $136.00
2014-01-30 Reiterated ISI Group Buy $121.50 to $130
2014-01-30 Boost Price Target Evercore ISI Buy $121.50 to $130.00
2014-01-30 Boost Price Target Mizuho Buy $130.00 to $140.00
2014-01-06 Reiterated ISI Group Buy $111 to $121.50
2014-01-06 Reiterated Rating Morgan Stanley Overweight $119.00 to $128.00
2014-01-06 Boost Price Target Evercore ISI Buy $111.00 to $121.50
2013-10-24 Boost Price Target Jefferies Group Buy $102.00 to $110.00
2013-10-24 Boost Price Target Cantor Fitzgerald $100.00 to $112.00
2013-09-27 Boost Price Target Goldman Sachs Neutral $89.00 to $94.00
2013-09-10 Reiterated Mizuho Buy $100 to $110
2013-07-25 Reiterated Cantor Fitzgerald Buy $96 to $100
2013-05-23 Reiterated Cantor Fitzgerald Buy $90 to $96
2013-04-24 Reiterated ISI Group Buy $90 to $92.50
2013-04-16 Upgrade Mizuho Neutral to Buy $80 to $90
2013-04-15 Reiterated Mizuho Neutral $65 to $85
2013-04-04 Downgrade WallachBeth Buy to Hold $68 to $76
2013-01-31 Reiterated ISI Group Buy $73.50 to $81
2016-07-06 Reiterated Rating Goldman Sachs Group Inc. Buy
2016-05-29 Reiterated Rating Leerink Swann Buy
2016-05-27 Boost Price Target Mizuho Buy $166.00 to $170.00
2016-05-27 Reiterated Rating BTIG Research Neutral
2016-05-19 Reiterated Rating Morgan Stanley Buy

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
CASPER MARC N Chief Executive Officer 0.07%  (294621) TMO / USB / ZMH /
Stevenson Mark Executive Vice President 0.02%  (82022) LIFE / TMO /
Pesicka Edward A Senior Vice President 0.02%  (80641) TMO /
SPERLING SCOTT M 0.02%  (73164) MSG / TMO /
WILVER PETER M Sr. VP & CFO 0.02%  (62517) AQUA / CIR / THC / TMO /
Thomson Andrew J Senior Vice President 0.01%  (52389) TMO /
Lagarde Michel Senior Vice President 0.01%  (48342) PTHN / TMO /
Malus Alan J Executive Vice President 0.01%  (47286) TMO /
MANZI JIM P 0.01%  (39757) TMO /
Williamson Stephen Sr. VP and CFO 0.01%  (39465) IFF / TMO /
Loewald Thomas W Senior Vice President 0.01%  (38133) HBIO / TMO /
Durbin Patrick M Senior Vice President 0.01%  (36677) TMO /
Herrema Gregory J. Senior Vice President 0.01%  (36435) TMO /
HOOGASIAN SETH H Sr. VP, Gen. Counsel & Sec. 0.01%  (26530) TMO /
Shine Daniel P Senior Vice President 0.01%  (20682) TMO /